Fundraising Fox
/Companies
Sign in

Zenas Biopharma

NASDAQ: ZBIO

Waltham, US · Founded 2019 · Delaware corporation · 200 employees on LinkedIn · 10 known investors

Find your way into Zenas Biopharma

Sign up to see every warm intro you have to Zenas Biopharma

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Zenas Biopharma team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Zenas BioPharma is a biopharmaceutical company developing therapies for autoimmune diseases, with two late-stage drug candidates: obexelimab, a bifunctional monoclonal antibody targeting CD19 and FcγRIIb to suppress B cell activity, and orelabrutinib, an oral BTK inhibitor. Its products are aimed at patients with multiple autoimmune conditions with unmet medical needs.

BiotechHealthtech

Founders & leadership

Zenas Biopharma was founded in 2019 by LEON O. MOULDER, JR. and Lonnie Moulder.

LOLEON O. MOULDER, JR.
LEON O. MOULDER, JR.Co-founder
LMLonnie Moulder
Lonnie MoulderFounder
JF
JOSEPH FARMERExecutive
HMHUA MU
HUA MUCEO, President, Acting CMO, China Head2021–2023He brings over 30 years of experience in drug development across oncology, autoimmune diseases, and neurology, with leadership roles spanning large pharmaceutical companies, biotech firms, CROs, and investment organizations in the US, Japan, and China.

Board

PGPATRICK GERALD ENRIGHT
PATRICK GERALD ENRIGHTBoard MemberManaging Director at Longitude Capital
HL
HONGBO LUBoard director
TK
TOMAS KISELAKBoard director
JJJOHN JACOB ORLOFF
JOHN JACOB ORLOFFBoard directorVenture Partner at Agent Capital
JPJAMES PATRICK BOYLAN
JAMES PATRICK BOYLANBoard directorChief Executive Officer at Enavate Sciences
MWMARIETTA WU
MARIETTA WUBoard directorManaging Director at Quan Capital

Investors · 10

Longitude Capitallisted by Longitude CapitalMenlo Park · $10M – $30M

How we know: Longitude Capital's portfolio page · the S-1 prospectus · the VCSheet dataset · Not right? Tell us

New Enterprise Associates (NEA)listed by New Enterprise Associates (NEA)Menlo Park · $200K – $40M

How we know: the S-1 prospectus · open dataset · 5k.vc investor directory · Not right? Tell us

Norwest Venture Partnerslisted by Norwest Venture PartnersMenlo Park · $10M – $30M

How we know: open dataset · 5k.vc investor directory · Not right? Tell us

Pivotal Life Scienceslisted by Pivotal Life SciencesSan Francisco

How we know: Pivotal Life Sciences's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

Quan Capitallisted by Quan CapitalShanghai
SR One Capital Managementlisted by SR One Capital ManagementRedwood City

How we know: SR One Capital Management's portfolio page · board seat on SEC Form D · Not right? Tell us

Vivo Capitallisted by Vivo CapitalPalo Alto · $10M – $50M

How we know: Vivo Capital's portfolio page · a partner's Signal profile · open dataset · 5k.vc investor directory · Not right? Tell us

Wellington Managementlisted by Wellington ManagementBoston · $5M – $50M
Agent CapitalreportedWalthamvia John Orloff · board

How we know: board seat on SEC Form D · the VCSheet dataset · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$384M disclosed across 2 rounds · 2022–2024

▶$200.1MraisedMay 2024 · 26 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • PATRICK GERALD ENRIGHTDirector
  • TOMAS KISELAKDirector
  • PATRICIA ALLENDirector
  • JOSEPH FARMERExecutive Officer
  • LEON O. MOULDER, JR.Executive Officer, Director
  • JAKE NUNNDirector
  • TIM XIAODirector
  • JENNIFER FOXExecutive Officer
  • JAMES PATRICK BOYLANDirector
  • TANYA Z. FISCHERExecutive Officer
  • JOHN JACOB ORLOFFDirector
  • HONGBO LUDirector
Offering amount
$200.1M
Amount sold
$200.1M
First sale
May 2024
Incorporated
Corporation, Delaware, 2023
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$183.9MraisedNov 2022 · 17 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • JOSEPH FARMERExecutive Officer
  • PATRICK GERALD ENRIGHTDirector
  • HONGBO LUDirector
  • TOMAS KISELAKDirector
  • LEON O. MOULDER, JR.Director
  • JOHN JACOB ORLOFFDirector
  • JAMES PATRICK BOYLANDirector
  • HUA MUExecutive Officer, Director
  • MARIETTA WUDirector
Offering amount
$183.9M
Amount sold
$183.9M
First sale
Nov 2022
Incorporated
Other, Cayman Islands, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events
$676.5Mvaluation at IPOSep 2024 · $17.00/share · 424B4
filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Related companies · 5

RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Day One BiopharmaceuticalsDay One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors. Founded in 2018, it received its first FDA approval in 2024 for a pediatric brain tumor treatment.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.

Companies working in the same space as Zenas Biopharma.

Frequently asked questions

What does Zenas Biopharma do?
Zenas BioPharma is a biopharmaceutical company developing therapies for autoimmune diseases, with two late-stage drug candidates: obexelimab, a bifunctional monoclonal antibody targeting CD19 and FcγRIIb to suppress B cell activity, and orelabrutinib, an oral BTK inhibitor. Its products are aimed at patients with multiple autoimmune conditions with unmet medical needs.
Who founded Zenas Biopharma?
Zenas Biopharma was founded by LEON O. MOULDER, JR., Lonnie Moulder in 2019.
Who are Zenas Biopharma's investors?
Zenas Biopharma's investors include Delos Capital, Longitude Capital, New Enterprise Associates (NEA), Norwest Venture Partners, Pivotal Life Sciences, Quan Capital, SR One Capital Management, Vivo Capital and 2 more.
How much funding has Zenas Biopharma raised?
Zenas Biopharma has disclosed $384M raised across 2 rounds.
Where is Zenas Biopharma headquartered?
Zenas Biopharma is headquartered in Waltham, US.